Data Show Racial/Ethnic Disparities in Pediatric Brain Cancer Survival
Clinical trial access alone appears to be insufficient in overcoming the worse survival outcomes observed in Black and Hispanic pediatric populations.
Related Articles
Acalabrutinib Combo Receives EU Approval for Mantle Cell Lymphoma
Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.
Leveraging Beta and Alpha Emitters in Metastatic CRPC Management
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
What Does It Mean to Experience Workplace Burnout as an Oncologist?
Workplace burnout in medicine and oncology can lead to stress, exhaustion, fatigue, and a lack of interest in work, according to Eric P. Winer, MD.
FDA Gives Fast Track Designation to Givinostat for Polycythemia Vera
The phase 3 GIV-IN PV trial is evaluating the efficacy and safety of givinostat vs hydroxyurea in patients with polycythemia vera.
Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma
Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.
FACE-OFF: Northwestern vs University of Chicago
Experts from Northwestern University and the University of Chicago present data and debate treatment practices in the non–small cell lung cancer space.
Melphalan/Hepatic Delivery System Demonstrates Benefit in Uveal Melanoma
No treatment-related deaths were observed among patients with metastatic uveal melanoma treated with melphalan and a hepatic delivery system.
Multidisciplinary Breast Cancer Clinic Improves Time to First Treatment
Utilizing a multidisciplinary breast cancer clinic helped improve time to first appointment and time to first treatment.
FDA Clears IND Application for TROP-2 Targeting ADC in Solid Tumors
Preclinical data showing OBI-902 sustained antitumor activity in solid tumors support the agency’s decision for the IND application.